Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TPI 287

Drug Profile

TPI 287

Alternative Names: ARC-100; NBT 287; TPI-287

Latest Information Update: 12 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tapestry Pharmaceuticals
  • Developer Cortice Biosciences; H. Lee Moffitt Cancer Center and Research Institute; Tapestry Pharmaceuticals; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; Van Andel Research Institute
  • Class Antineoplastics; Taxanes
  • Mechanism of Action Microtubule protein modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Glioblastoma
  • Phase I/II Malignant melanoma
  • Phase I Alzheimer's disease; Corticobasal degeneration; Non-small cell lung cancer; Progressive supranuclear palsy
  • No development reported Cancer; Medulloblastoma; Neuroblastoma
  • Discontinued Pancreatic cancer; Prostate cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Apr 2018 Cortice Biosciences temporarily suspends a phase II trial for Glioblastoma (recurrent; combination therapy) for financial reasons in USA (NCT01933815)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Alzheimer's-disease in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top